Navigation Links
Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
Date:3/17/2009

ROCKVILLE, Md., March 17 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its 2008 fourth quarter financial results in a press release to be issued after 8:00 a.m. Eastern Time on March 30, 2009. The Company will hold an investor conference call to discuss its financial results at 10:00 a.m. Eastern Time on March 30, 2009. The call will be hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of senior management. A question and answer session will follow the financial results overview. The dial-in number for the conference call is USA and Canada (866) 206-6509 International: (703) 639-1108.

A live audio webcast of the conference call will be available at www.novavax.com. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available for 90 days after the webcast and a replay of the conference call will also be available by telephone beginning 1pm EDT. March 30, 2009 through midnight April 1, 2009. To access the replay, dial (888) 266-2081 and enter pass code 1334845.

About Novavax, Inc.

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looki
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
2. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
3. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
4. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
5. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
6. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
7. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
8. Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference
9. Novavax CEO to Present at Lazard Capital Markets 5th Annual Healthcare Conference
10. Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
11. Novavax CEO to Present at Oppenheimer 19th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... NEW YORK , July 29, 2015 /PRNewswire/ ... neuropathology testing, announces increased partnerships with VA and ... offers Epidermal Nerve Fiber Density (ENFD) and Sweat ... of small fiber neuropathy ( https://therapath.com/skin ). ... Epidermal Nerve Fiber Density (ENFD) on punch skin ...
(Date:7/29/2015)... NJ (PRWEB) , ... July 29, 2015 , ... The ... approval of combination products , in particular, drug/device combinations. The current system received ... by the Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ...
(Date:7/29/2015)... , ... July 29, 2015 , ... Finding gooey or ... is quite normal. Although there are a considerable number of terms in popular use ... this post-sleep material is a mixture of mucus, blood cells, skin cells and dust, ...
(Date:7/29/2015)... ... ... Costello served as Lead Levee Design Engineering Manager for a feasibility study ... from future storm surge flooding, such as occurred in Hurricane Ike in 2008. ... providing protection, Costello also balanced socio-economic and environmental needs and concerns. The ...
Breaking Biology Technology:Neuropathology services for VA and Military health systems 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4Preventing Storm Surge Flooding in Houston 2
... - Helix BioPharma Corp.,(TSX, FSE: "HBP"), a biopharmaceutical ... announced its product development progress, quarterly,highlights and financial ... ended,April 30, 2008., "During the quarter, we ... clinical compounds," said John Docherty, President,of Helix Biopharma. ...
... Interim Results Show Promise for Improving the Treatment of Blockages ... ... /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), ... its corporate partner, Cook,Medical, has reported positive interim results from ...
... for,Analytical Cytometry has bestowed its President,s Award for ... work on the discovery and,characterization of embryonic-like stem ... Institute of the University of Louisville and has,employed ... "I am highly honored to have been ...
Cached Biology Technology:Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 2Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 3Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 4Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 5Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 6Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 7Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 8Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 9Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 10Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 11Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 12Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 13Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 14Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 15Angiotech's corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study 2Angiotech's corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study 3Angiotech's corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study 4Angiotech's corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study 5Stem Cell Researcher Wins Award for Excellence for Work With the ImageStream(R) System 2